Analysis of prognostic factors of intermediate risk gastrointestinal stromal tumors

王力,高晓东,方勇,薛安慰,侯英勇,李鹤,凌佳倩,束平,沈坤堂,秦净,孙益红,秦新裕

DOI: https://doi.org/10.19538/j.cjps.issn1005-2208.2017.01.22

2017-01-01

Abstract:Objective To investigate the clinical and pathological characteristics and the effect of imatinib (IM) adjuvant therapy on the prognosis of intermediate risk gastrointestinal stromal tumors(GIST). Methods The clinical data and follow-up data of 123 patients with intermediate risk GIST confirmed by pathology in Zhongshan Hospital Affiliated to Fudan University between January 2003 and December 2013 were analyzed retrospectively. Results There were 64 male and 59 female patients with a median age of 58 months (24-150). The major clinical symptoms were abdominal pain, abdominal distension (30.1%,37 cases), followed by hemorrhage, anemia (16.3%,20 cases). One of 27 patients who received adjuvant IM experienced liver metastasis while 5 of 96 patients without had recurrence or metastases. Among 6 patients, according to WHO evaluation criteria, 3 cases were malignant, 3 cases were benign;according to the morphological criteria, 5 cases were malignant, 1 cases were borderline. Disease-free survival rates of 1-, 3-, and 5-years were 100.0%,95.8%,95.8%in patients taking IM, respectively. DFS rates of 1-, 3-, and 5-years were 98.9%,97.9%,94.4%in patients without taking IM, respectively. There was no obvious statistical difference in the DFS rates between the two groups (P=0.760). WHO benign and malignant evaluation, 82 cases of benign GIST and 41 cases of malignant GIST, there was no significant difference in DFS between the two groups (P=0.450). According to the pathological morphological index, GIST was divided into malignant and non-malignant, and there was a significant statistical difference between the two groups(P=0.017). Conclusions Adjuvant use of IM without selection didn’t benefit patients classified as NIH intermediate risk GIST after R0 surgery. However, the pathologically morphological index identifies those with relatively high potential of malignancy and requiring adjuvant IM.